TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32645158

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 82
Study: 35347848

Group type: EXPERIMENTAL
Intervention: Weight control strategies total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological coping subscale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline BMI
Number of subjects: 0
Study: 34211015

Group type: EXPERIMENTAL
Intervention: ΔQRS ≥ 8 ms (group 3)
Number of subjects: 798

Group type: COMPARATOR
Intervention: ΔQRS < 4 ms (group 1)
Number of subjects: 798
Study: 35157001

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 0
Study: 33393452

Group type: EXPERIMENTAL
Intervention: Overweight condition
Number of subjects: 130

Group type: COMPARATOR
Intervention: Underweight condition
Number of subjects: 130
Study: 33745505

Group type: EXPERIMENTAL
Intervention: TSD therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: MAD therapy
Number of subjects: 39
Study: 32092608

Group type: EXPERIMENTAL
Intervention: Microbreaks every 10 minutes for 10 seconds
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal procedures (without microbreaks)
Number of subjects: 12
Study: 35850745

Group type: EXPERIMENTAL
Intervention: Neck specific or general exercise intervention
Number of subjects: 172
Study: 32175662

Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg injected into the coronary artery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (equal volume injected into the coronary artery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 60
Study: 36195924

Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 759

Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 759
Study: 33952670

Group type: EXPERIMENTAL
Intervention: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Number of subjects: 0

Group type: COMPARATOR
Intervention: clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Number of subjects: 0
Study: 35198025

Group type: EXPERIMENTAL
Intervention: Normal vitamin D3 level group (ND3G)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study: 32361875

Group type: EXPERIMENTAL
Intervention: SD2 (suprapubic tube with micturition on POD 2)
Number of subjects: 198

Group type: COMPARATOR
Intervention: TD5 (transurethral catheter with micturition on POD 5)
Number of subjects: 198

Group type: COMPARATOR
Intervention: SD5 (suprapubic tube with micturition on POD 5)
Number of subjects: 198
Study: 33080730

Group type: COMPARATOR
Intervention: DACPR with metronome sounds (mDACPR)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: DACPR with metronome sounds and human encouragement (mheDACPR)
Number of subjects: 69
Study: 35572164

Group type: EXPERIMENTAL
Intervention: RFE under NMES
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 99
Study: 33227454

Group type: EXPERIMENTAL
Intervention: Predeposit autotransfusion (PAT) after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no blood transfusion after surgery)
Number of subjects: 0
Study: 36224244

Group type: EXPERIMENTAL
Intervention: Active M1‐rTMS (10 Hz for 10 daily treatments over 2 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham M1‐rTMS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active M1‐rTMS
Number of subjects: 27
Study: 34352094

Group type: EXPERIMENTAL
Intervention: Undifferentiated arthritis (UA)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Autoantibody-negative rheumatoid arthritis (RA-)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Autoantibody-positive rheumatoid arthritis (RA+)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 637
Study: 33147621

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (200/50 mg levodopa-benserazide)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (OFF medication)
Number of subjects: 63
Study: 36461704

Group type: EXPERIMENTAL
Intervention: 6 mm short implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: 11 mm long implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study: 32128718

Group type: EXPERIMENTAL
Intervention: After once artificial abortion (AOAA)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: After twice artificial abortion (ATAA)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: After three times or more artificial abortion (ATTMAA)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Normal control group (NC)
Number of subjects: 254
Study: 36482733

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 47
Study: 34930841

Group type: EXPERIMENTAL
Intervention: Emails from ostensibly Black senders
Number of subjects: 250000

Group type: COMPARATOR
Intervention: Emails from ostensibly White senders
Number of subjects: 250000
Study: 34431186

Group type: EXPERIMENTAL
Intervention: Barostat-assisted sensory training (BAST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Syringe-assisted sensory training (SAST)
Number of subjects: 66
Study: 33298154

Group type: EXPERIMENTAL
Intervention: Duloxetine, antivirals, and analgesics
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control (antivirals and analgesics only)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 750
Study: 34344428

Group type: EXPERIMENTAL
Intervention: Culture‐directed antibacterial therapy based on percutaneous bone biopsy culture results
Number of subjects: 80

Group type: COMPARATOR
Intervention: Culture‐directed antibacterial therapy based on ulcer bed biopsy culture results
Number of subjects: 80
Study: 32367393

Group type: EXPERIMENTAL
Intervention: Triple airway maneuver
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 103
Study: 32091293

Group type: EXPERIMENTAL
Intervention: Video livestream from a smartphone during telephone-assisted CPR
Number of subjects: 46
Study: 33860324

Group type: EXPERIMENTAL
Intervention: SNP selection strategy using a combination of mean minor allele frequency (MAF) and linkage disequilibrium (LD)
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Random SNP selection
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: SNP categorized as low MAF (0.01 < MAF ≤ 0.1)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: SNP located on autosomal extremes
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Genotyping panel consisting of 10,000 SNP selected based on breed-specific selection criteria
Number of subjects: 1135
Study: 33992256

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) applied using a cluster device (Laser + LED), three times a week for four weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 33248591

Group type: EXPERIMENTAL
Intervention: Simulated transport at -10°C uncontrolled RH
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at +30°C 30%RH
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at +30°C 80%RH
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at +21°C 30%RH
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at +21°C 80%RH
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at +30°C 30%RH for prolonged duration
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Simulated transport at -10°C for prolonged duration
Number of subjects: 540
Study: 35354620

Group type: EXPERIMENTAL
Intervention: Decentering training for 5 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Active control group (light physical exercise and cognitive training)
Number of subjects: 57
Study: 33609457

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 560

Group type: COMPARATOR
Intervention: Delayed BCG vaccination (at age 6 weeks)
Number of subjects: 560
Study: 32132639

Group type: EXPERIMENTAL
Intervention: Video intervention designed to demonstrate the consequences of disadvantageous choices
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 34319268

Group type: EXPERIMENTAL
Intervention: Manikin-based simulation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case discussion
Number of subjects: 0
Study: 34132690

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 36
Study: 35420254

Group type: EXPERIMENTAL
Intervention: Single Perclose device
Number of subjects: 506

Group type: COMPARATOR
Intervention: Double Perclose device
Number of subjects: 506
Study: 33533320

Group type: EXPERIMENTAL
Intervention: HFCS-sweetened soft drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened soft drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 34890214

Group type: EXPERIMENTAL
Intervention: AC-THP (Taxane + Trastuzumab + Pertuzumab)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: AC-KP (Trastuzumab Emtansine + Pertuzumab)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: AC-THP
Number of subjects: 1846

Group type: COMPARATOR
Intervention: AC-KP
Number of subjects: 1846
Study: 33243277

Group type: EXPERIMENTAL
Intervention: Double Sequential External Defibrillation (DSED)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vector Change (VC) Defibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Defibrillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DSED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early DSED (first DSED shock is shock 4–6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late DSED (first DSED shock is shock 7 or later)
Number of subjects: 0
Study: 33313768

Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy
Number of subjects: 756

Group type: COMPARATOR
Intervention: Unbiopsied blastocysts
Number of subjects: 756
Study: 34809506

Group type: EXPERIMENTAL
Intervention: Interrupted every 20 min with 1 min light intensity half squats plus calf raises (EX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uninterrupted sitting (CON)
Number of subjects: 20
Study: 33704698

Group type: EXPERIMENTAL
Intervention: Higher doses of exercise training
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Lower doses of exercise training
Number of subjects: 1590
Study: 33020354

Group type: EXPERIMENTAL
Intervention: S One Group I (new instruments)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: S One Group II (used instruments after ex vivo treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Group I and Group II for S One and M-Two
Number of subjects: 20
Study: 35274747

Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management (TCM) programme
Number of subjects: 44
Study: 34088381

Group type: EXPERIMENTAL
Intervention: Multi-component communication intervention on conversations regarding ICD deactivation and advance care planning
Number of subjects: 407

Group type: COMPARATOR
Intervention: Physician estimated prognosis of < 1 year
Number of subjects: 407

Group type: COMPARATOR
Intervention: Physician estimated prognosis of > 1 year
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Overall patient-physician prognostic concordance (PPPC)
Number of subjects: 407
Study: 36074963

Group type: EXPERIMENTAL
Intervention: 24% Su
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 25% Su
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 30% Su
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: LC 15‐min
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: LC 30‐min
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: LC 45‐min
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of 24% Su and LC 30 minutes before puncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 300
Study: 33546737

Group type: EXPERIMENTAL
Intervention: Connect‐Home intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard discharge planning
Number of subjects: 360
Study: 32403367

Group type: EXPERIMENTAL
Intervention: Glucose-based TPN (group G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid-based TPN (group L)
Number of subjects: 0
Study: 36109546

Group type: EXPERIMENTAL
Intervention: Quiz group (n=26, attractive-type nudges)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Implementation intentions group (n=25, social-type nudges)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Growth mindset group (n=25, timely-type nudges)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Reference group (n=36, no nudges)
Number of subjects: 112
Study: 33994294

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study: 32248227

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) with home exercise program (HEP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) with home exercise program (HEP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined NMES/TENS with home exercise program (HEP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active home exercise program (HEP) only
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All electrical stimulation groups (NMES, TENS, NMES/TENS)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All treatment groups (NMES, TENS, NMES/TENS)
Number of subjects: 130
Study: 35961180

Group type: EXPERIMENTAL
Intervention: Tailored computer program (MAPS)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Non-tailored control video
Number of subjects: 304
Study: 35738655

Group type: EXPERIMENTAL
Intervention: Co-designed health and education model intervention involving regular case-based discussions and paediatric support
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (half of the schools)
Number of subjects: 12
Study: 32697484

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (n = 405)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin
Number of subjects: 800
Study: 35392841

Group type: EXPERIMENTAL
Intervention: 0.02% atropine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (SV spectacles only)
Number of subjects: 400
Study: 36317342

Group type: EXPERIMENTAL
Intervention: Surgical fixation with Kirschner wire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moulded casting
Number of subjects: 0
Study: 33910230

Group type: EXPERIMENTAL
Intervention: Less-intensive therapies
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Intensive therapies
Number of subjects: 1987
Study: 35038337

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity physical education class (LIPE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined group (PLUS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High‐intensity physical education class (HIPE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard physical education lessons (CTRL)
Number of subjects: 120
Study: 34585137

Group type: EXPERIMENTAL
Intervention: Mobile app-based training for health literacy, 8 weeks duration, content read once a week
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 36334223

Group type: EXPERIMENTAL
Intervention: Celery seed extract (1.34 g per day)
Number of subjects: 50
Study: 35725254

Group type: EXPERIMENTAL
Intervention: WHO-CST (Caregiver Skills Training)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 130
Study: 32180692

Group type: EXPERIMENTAL
Intervention: Fish group receiving fatty fish three times per week
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group receiving an alternative meal (e.g. chicken, pork, and beef)
Number of subjects: 81
Study: 35894881

Group type: EXPERIMENTAL
Intervention: Integrated functional core and plyometric training program (CPT) for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual training sessions
Number of subjects: 44
Study: 33349280

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I); 8 sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture; 10 sessions
Number of subjects: 0
Study: 34405412

Group type: EXPERIMENTAL
Intervention: Structured lipids (SLs) obtained from chemical interesterification (CIE) of blends with 60-70% wt. palm kernel stearin (PKS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical blends (PBs) of palm kernel stearin, coconut oil, and fully hydrogenated palm stearin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocoa butter alternatives (CBAs)
Number of subjects: 0
Study: 34102947

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Normo Prehab
Number of subjects: 3
Study: 32198306

Group type: EXPERIMENTAL
Intervention: Peer reviewers receive a reminder and short explanation of the 10 most important and poorly reported CONSORT items; they check if these items are reported in the submitted manuscript.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual journal practice (control group).
Number of subjects: 166
Study: 36327271

Group type: EXPERIMENTAL
Intervention: Larviciding intervention in urban areas
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-intervention areas
Number of subjects: 26
Study: 33730722

Group type: EXPERIMENTAL
Intervention: Ginseng (twice daily for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (twice daily for 4 weeks)
Number of subjects: 60
Study: 35726506

Group type: EXPERIMENTAL
Intervention: Oral Isotretinoin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 32554534

Group type: EXPERIMENTAL
Intervention: ARD-3150 (inhaled liposomal ciprofloxacin)
Number of subjects: 0
Study: 33310418

Group type: EXPERIMENTAL
Intervention: eculizumab (1200 mg/2 weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: eculizumab
Number of subjects: 143
Study: 32305398

Group type: EXPERIMENTAL
Intervention: Balloon-expandable (BE) valve
Number of subjects: 241

Group type: COMPARATOR
Intervention: Self-expanding (SE) valve
Number of subjects: 241
Study: 36254415

Group type: EXPERIMENTAL
Intervention: Simple technique
Number of subjects: 114

Group type: COMPARATOR
Intervention: Classical technique
Number of subjects: 114
Study: 32460799

Group type: EXPERIMENTAL
Intervention: Culturally-adapted minimal-guidance online self-help program (8-week 'Selge' online program)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control condition (self-administered test of alcohol use and advice regarding usual treatment in Estonia)
Number of subjects: 600
Study: 35590348

Group type: EXPERIMENTAL
Intervention: In-person CETA delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth-delivered CETA (T-CETA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CETA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-CETA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study: 33663538

Group type: EXPERIMENTAL
Intervention: Higher resilience scores
Number of subjects: 575
Study: 34424995

Group type: EXPERIMENTAL
Intervention: Colloid-based priming solution (dextran 40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Crystalloid-based priming solution (Ringer-Acetate plus mannitol)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 33854007

Group type: EXPERIMENTAL
Intervention: UIC201609/UIC201610 (combination of rabeprazole and CR mosapride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: rabeprazole 10 mg once a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: mosapride 15 mg CR tablet once a day
Number of subjects: 30
Study: 34674209

Group type: EXPERIMENTAL
Intervention: Budesonide slurry
Number of subjects: 111

Group type: COMPARATOR
Intervention: Swallowed fluticasone multidose inhaler
Number of subjects: 111
Study: 34662498

Group type: EXPERIMENTAL
Intervention: Prophylactic apixaban
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 33027266

Group type: EXPERIMENTAL
Intervention: Urban health zones
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Savannah landscape
Number of subjects: 515

Group type: COMPARATOR
Intervention: Climate types
Number of subjects: 515

Group type: COMPARATOR
Intervention: Health zones
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Vegetation types
Number of subjects: 515
Study: 35727536

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erenumab (both doses)
Number of subjects: 25
Study: 33463426

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPN) irrigation solution (0.33 mg per 1 L of saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) irrigation solution (0.42 mg per 1 L of saline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: EPN
Number of subjects: 90

Group type: COMPARATOR
Intervention: TXA
Number of subjects: 90